UNITY Biotechnology expands trial of osteoarthritis senolytic


UBX0101 currently in phase 1 trial for osteoarthritis (OA) of the knee.
UNITY Biotechnology encouraged by the safety and tolerability results so far.
Enrolling an additional 24 patients at the highest evaluated dose (4mg).
Part B of trial will provide an increased sample size for SASP assessment .
Will enable further evaluation the impact of UBX0101 on SASP.
Human clinical trial is the first study of a senolytic drug in patients with OA.

Initial results must be promising to enrol more patients at highest dosage
Read full article on UNITY Biotechnology website
More Senescent Cells information, news and resources